Weekly Digest

Advances in the biomedical industry are often a function of quality research produced at academic research institutions around the world. This year's list of top R&D outposts had a number of changes, namely the addition of more Chinese institutions.

The lack for adequate options to treat major depressive disorder has been well documented. Then came the pandemic, adding more patients diagnosed with MDD and heightening the unmet need. With that, the timing is good for the approval of a potentially game-changing drug to treat MDD. On Friday, the FDA signed off on Axsome Therapeutics’ Auvelity, the first rapid-acting oral treatment for MDD.

A former Kadmon consultant pled guilty to insider trading ahead of Sanofi's September 2021 buyout of the small drugmaker. Frank Glassner made $368,000 trading off of nonpublic information, the feds say.

A spinal cord stimulation device newly approved in the U.S. one-ups other pain relief devices—or, perhaps, six-ups them—by treating multiple areas of the body at once.

More than a month after axing 94 employees, PACT Pharma is culling its lead asset and diverting 54 of the laid-off employees to a new business development venture that's yet to be named.

Teva Parenteral Medicines is letting go of 305 staffers at its site at 19 Hughes, Irvine, California, according to a local Worker Adjustment and Retraining Notification Act notice. In a statement, the company said it's moving to close the troubled site.

Former Takeda exec Thomas Willemsen will be taking the reins as Tessa Therapeutics' new president and CEO as the CAR-T biotech gears up in anticipation of several clinical milestones.

BeiGene is building up its oncology franchise but, to help boost awareness of cancer drugs, is tapping McKesson’s real-world evidence business Ontada for a series of new campaigns.

Cancer-associated fibroblasts are commonly believed to induce drug resistance. But when researchers at Moffitt Cancer Center took a closer look at the fibroblasts, they discovered that while some induce drug resistance, some induce drug sensitivity.

This week on "The Top Line," we discuss Genentech’s Greg Rippon's remarks on missing the mark in terms of diverse trial recruitment and how the company hopes to get it right in the future. We'll also chat about a new report on brand awareness for diabetes drugs.

Each year at Fierce, we spotlight women who are leading the way in the life sciences, from industry professionals and academics to venture capitalists and regulatory officials.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.